Cytek Biosciences (CTKB) Expected to Announce Earnings on Wednesday

Cytek Biosciences (NASDAQ:CTKB) is projected to release its Q3 2025 results after the market closes on Wednesday, November 5th. Analysts expect Cytek Biosciences to post earnings of $0.01 per share and revenue of $51.4880 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 4:30 PM ET.

Cytek Biosciences (NASDAQ:CTKB) last released its quarterly earnings data on Tuesday, November 28th. The company reported $0.04 earnings per share (EPS) for the quarter. The business had revenue of $40.48 million for the quarter. Cytek Biosciences had a negative return on equity of 1.66% and a negative net margin of 3.27%.

Cytek Biosciences Trading Up 1.2%

Shares of NASDAQ CTKB opened at $4.20 on Wednesday. The firm has a market capitalization of $534.32 million, a price-to-earnings ratio of -84.00 and a beta of 1.31. Cytek Biosciences has a one year low of $2.37 and a one year high of $7.63. The business has a fifty day simple moving average of $3.94 and a 200 day simple moving average of $3.59.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Topline Capital Management LLC grew its position in Cytek Biosciences by 255.7% during the 2nd quarter. Topline Capital Management LLC now owns 5,231,260 shares of the company’s stock worth $17,786,000 after acquiring an additional 3,760,485 shares during the last quarter. AQR Capital Management LLC grew its holdings in shares of Cytek Biosciences by 89.6% during the second quarter. AQR Capital Management LLC now owns 1,238,393 shares of the company’s stock worth $4,211,000 after purchasing an additional 585,116 shares during the last quarter. Jane Street Group LLC increased its stake in shares of Cytek Biosciences by 412.2% in the first quarter. Jane Street Group LLC now owns 344,169 shares of the company’s stock valued at $1,380,000 after buying an additional 276,972 shares in the last quarter. Marshall Wace LLP bought a new position in shares of Cytek Biosciences in the second quarter valued at about $889,000. Finally, Ameriprise Financial Inc. lifted its position in Cytek Biosciences by 48.7% during the 2nd quarter. Ameriprise Financial Inc. now owns 412,311 shares of the company’s stock worth $1,402,000 after buying an additional 134,963 shares in the last quarter. Institutional investors own 69.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on CTKB shares. Zacks Research raised shares of Cytek Biosciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 6th. Weiss Ratings restated a “sell (e+)” rating on shares of Cytek Biosciences in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $5.60.

Cytek Biosciences Company Profile

Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.